medwireNews: A heightened pro-inflammatory cytokine profile has been found in patients with Parkinson’s disease (PD), supporting clinical evidence that the condition is accompanied by an inflammatory response.
“The study provides a novel perspective into the etiology of PD, and future investigations into the cytokines as biomarkers and therapeutic targets for PD may be warranted”, say Yong Cheng (National Institutes of Health, Bethesda, Maryland, USA) and co-authors in JAMA Neurology.
The specific cytokines found to be significantly increased in patients with PD versus healthy individuals were interleukin (IL)-6, tumour necrosis factor, IL-1β, IL-2, IL-10 and C-reactive protein, along with the chemokine RANTES, which is associated with inflammatory cell recruitment.
The meta-analysis findings were based on data from 25 biomarker studies encompassing 1547 patients with PD and 1107 without.
But editorialist Roy Alcalay (Columbia University Medical Center, New York, USA) notes that there were insufficient data to determine the cytokines’ associations with disease characteristics, such as duration and severity, making it difficult to conclude whether the inflammatory biomarkers are a cause or result of the disease.
He believes “a better understanding of the mechanism linking PD and inflammation is required” before inflammation-modulating therapies can be offered to people with or at risk of developing PD.
By Lucy Piper
medwireNews is an independent medical news service provided by Springer Healthcare Limited. © Springer Healthcare Ltd; 2016